The Patent Finder
US

Stabilized Oxymetazoline Formulations and Their Uses

US 11,517,560 In force
OverviewFamilyAssignmentsSources & methods

Term ends Jun 11, 2035 · Low confidence

Filed Jul 9, 2020 as application 16/924,782 · Granted Dec 6, 2022
Base term, 20 years from filing
Today
20 years from filing
2015 2035
Clock starts
Jun 11, 2015
Term ends
Jun 11, 2035
Granted
Dec 6, 2022
base term fee events Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,335,391, US 10,751,325, US 9,801,857, US 9,974,773, to Jun 11, 2035. The term already ends on or before that date, so the cap shortened nothing.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: Low. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Jun 11, 2015, when application 14/737,360, the earliest non-provisional in its chain, was filed (this one was filed Jul 9, 2020); a parent in its chain could not be resolved (the next row)Jun 11, 2035High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 10,335,391, US 10,751,325, US 9,801,857, US 9,974,773)resolves to Jun 11, 2035, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 3 maintenance fees paidIn forceHigh confidence
Further caveats on recordThe record names parents not resolved: 15984918, 14737360, 14737360, 15984918Low confidence overallLow confidence
Computed term endThe steps above, in orderJun 11, 2035Low confidence

This family

US 9,801,857In force
Jun 2035
Jun 2035
US 9,974,773In force
Jun 2035
Jun 2035
US 10,335,391In force
Jun 2035
Jun 2035
US 10,751,325In force
Jun 2035
Jun 2035
US 11,517,560this patent
Jun 2035
Jun 2035
US 12,350,255In force
Jun 2035
Jun 2035
Application 19/210,851Pending
not computed
not computed
Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Mar 14, 2022
Reel 59364, frame 509
Epi Health, LLCEvening Post Group, LLCSecurity Interest
Jan 11, 2023
Reel 62347, frame 129
Evening Post Group, LLCEpi Health, LLCRelease of Security Interest
Dec 11, 2024
Reel 69557, frame 245
Sarpotdar, Pramod; Warner, Kevin; Ahluwalia, Gurpreet; Kuang, Amy; Zhang, StevenAllergan, Inc.Assignment of Assignor's Interest
Dec 11, 2024
Reel 69557, frame 318
Allergan, Inc.Aclaris Therapeutics, Inc.Assignment of Assignor's Interest
Dec 11, 2024
Reel 69557, frame 372
Epi Health, LLCMayne Pharma LLCAssignment of Assignor's Interest
Dec 11, 2024
Reel 69599, frame 614
Aclaris Therapeutics, Inc.Epi Health, LLCAssignment of Assignor's Interest
Oct 26, 2026
Reel 76754, frame 805
Epi Health, LLCMayne Pharma LLCCorrective Assignment to Correct the Properties Section by Including Application Numbers That Were Omitted from the Previously Recorded Assignment as Well as Include Pages Missing from Assignment Previously Recorded on Reel 69557 Frame 372. Assignor(S) Hereby Confirms the Assignment of Assignor's Interest.

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited